Capabilities by Industry: Healthcare

Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector.  Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia, Brazil and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.

In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.

Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals and biotechnology. 

Below we highlight a few of the transactions on which we have advised in this area:

Recent Transactions

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

06-Nov-06
$4.2 billion
United States flag
Target: 

Kos Pharmaceuticals, Inc.

United States flag
Acquiror: 
Abbott Laboratories

Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories

25-Jan-07
$3.3 billion
United States flag
Target: 

Cardinal Health, Inc., Pharmaceutical Technologies and Services division

United States flag
Acquiror: 
The Blackstone Group

Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a U.S. based provider of histopathology diagnostic equipment

12-Jun-08
$6.7 billion
United States flag
Target: 

Applied Biosystems Group

United States flag
Acquiror: 
Invitrogen Corporation

Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems

01-Oct-08
$53 million
Sweden flag
Target: 

Biotage (Biosystems division)

Netherlands flag
Acquiror: 
Qiagen NV

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

23-Jun-09
$155 million
United States flag
Target: 

Monogram Biosciences, Inc.

United States flag
Acquiror: 
Laboratory Corporation of America Holdings

Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

23-Feb-10
$NA
United States flag
Target: 

Heartscape Technologies, Inc.

United States flag
Acquiror: 
Roper Industries, Inc.

Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company

05-Apr-10
$225 million
United States flag
Target: 

Medegen, Inc

United States flag
Acquiror: 
CareFusion Corporation

Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company

12-Jul-10
$NA
United States flag
Target: 

Breast Care Business of Ethicon-Endo Surgery

United States flag
Acquiror: 
Devicor Medical Products, Inc. (a GTCR portfolio company)

Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery

21-Sep-10
$234 million
Israel flag
Target: 

Taro Pharmaceutical Industries

India flag
Acquiror: 
Sun Pharmaceutical Industries Ltd.

Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

07-Dec-10
$500 million
United States flag
Target: 

Medicity, Inc.

United States flag
Acquiror: 
Aetna Inc.

Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information

13-Dec-10
$256 million
United Kingdom flag
Target: 

Maxinutrition Group Holdings Limited

United Kingdom flag
Acquiror: 
GlaxoSmithKline Plc

Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

13-May-11
$NA
Australia flag
Target: 

Bionomics Ltd

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

30-Jun-11
$609 million
Japan flag
Target: 

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

United States flag
Acquiror: 
Royalty Pharma

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

07-Nov-11
$398 million
United States flag
Target: 

American Dental Partners, Inc.

United States flag
Acquiror: 
JLL Partners

Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

16-Dec-11
$NA
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives

26-Mar-12
$513 million
United States flag
Target: 

ISTA Pharmaceuticals, Inc.

United States flag
Acquiror: 
Bausch + Lomb, Inc.

Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company

01-Aug-12
$4.0 billion
South Africa, Switzerland flags
Target: 

Mediclinic International Limited

Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa

20-Aug-12
$7.3 billion
United States flag
Target: 

Coventry Health Care Inc.

United States flag
Acquiror: 
Aetna

Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna

Pages

show all